查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472260

HIV注射市場：依通路分類：2024-2033年全球機會分析與產業預測

HIV Injection Market By Distribution Channel (Hospital Pharmacy, Drugs Stores and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

HIV注射劑市場預計到2023年將達到10億美元，2024年至2033年複合年成長率為17.9%，到2033年將達到55億美元。

人類免疫力缺乏病毒 (HIV) 是一種攻擊免疫系統的病毒，特別是 CD4 細胞（T 細胞），可幫助免疫系統抵抗感染疾病。愛滋病毒主要透過無保護的性行為、共用污染的針頭以及分娩和哺乳期間受感染的母親傳播給嬰兒。抗逆轉錄病毒療法 (ART) 的進步顯著改善了愛滋病毒感染者的預後，有助於控制病毒、防止進展為愛滋病並提高整體生活品質。定期檢測、早期發現和獲得醫療保健對於控制愛滋病毒和防止其傳播至關重要。

HIV注射劑市場-IMG1

公眾意識、教育和持續研究對於全世界對抗這種感染疾病的努力至關重要。 HIV 注射旨在將抗逆轉錄病毒物直接輸送到血液中，保持體內藥物水平有效且恆定。這些注射劑有不同的形式，包括肌肉注射（注射到肌肉）和皮下注射（注射到皮下）。 HIV注射劑市場的促進因素包括：HIV感染者數量的增加、注射製劑中新型抗逆轉錄病毒藥物的開發和引入、對長效和長效HIV預防和治療方法的需求增加以及研究和開發活動的增加是由投資增加、政府針對愛滋病毒的舉措和擴大的醫療保健政策所推動的。

例如，根據聯合國愛滋病毒/愛滋病聯合規劃署 (UNAIDS) 的數據，到 2022 年，全球將有 3,900 萬人感染愛滋病毒。因此，愛滋病毒感染人數的增加將增加愛滋病毒注射劑的需求並推動市場成長。此外，愛滋病毒治療領域的持續研究和開發工作預計將帶來持續進步，並成為市場成長的驅動力。新型抗逆轉錄病毒藥物（尤其是注射劑）的推出為醫療保健專業人員和患者提供了更多的病毒管理選擇，從而推動了市場成長。例如，葛蘭素史克公司生產了一種治療愛滋病毒的長效注射抗逆轉錄病毒藥物，該藥物結合了卡博特韋和利匹韋林。此方案稱為 Cabenuva（Vocabria，歐洲為 Recambis），由肌肉注射 cabotegravir（一種整合酶抑制劑）和利匹韋林（一種非核苷逆轉錄酶抑制劑）組成。這種長效注射療法已在幾個高所得國家獲得核准，並顯示出維持病毒抑制的前景。

此外，旨在擴大愛滋病毒治療範圍和改善醫療基礎設施的政府措施和醫療政策正在發揮關鍵作用，預計將推動市場成長。例如，由美國衛生與公共服務部 (HHS)主導的終結愛滋病毒流行 (EHE)舉措旨在到 2025 年和 2030 年將美國新發愛滋病毒感染人數減少 75%。 HHS 致力於利用愛滋病毒預防、診斷、治療和疫情應對方面的科學進步來解決種族、民族和地理差異。

然而，低度開發國家嚴格的核准監管程序和缺乏愛滋病預防教育是阻礙愛滋病注射市場成長的因素。相較之下，愛滋病毒藥物的不斷增加和新興國家的高成長潛力為市場成長提供了有利的機會。例如，臨床階段免疫治療公司 ImmunityBio, Inc. 於 2021 年 6 月宣布了其 HIV 臨床管道，目前正在美國招募參與者，其中包括 Anktiva (N-803) 的 HIV 治癒試驗。該試驗預計將檢驗在參與者停止抗逆轉錄病毒治療（ART）並受到密切監測後，Anktiva 是否可以單獨或合併中和抗體（bNAB）控制 HIV。

HIV注射劑市場按分銷管道和地區分類。依分銷管道分類，市場分為醫院藥房、藥局和零售藥房等。依地區分類，我們有北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家地區）、亞太地區（日本、中國、印度、澳洲、韓國、其他亞洲地區）太平洋地區）、拉丁美洲、中東和非洲（巴西、中國、非洲、阿拉伯、拉丁美洲其他地區、中東和非洲）。

相關人員的主要利益

  • 本報告定量分析了 2023 年至 2033 年 HIV 注射市場的細分市場、當前趨勢、估計/趨勢和動態，並確定了 HIV 注射市場的強大機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商和買家網路的潛力。
  • 對愛滋病毒注射市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球愛滋病毒注射市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

報告客製化的可能性（請聯絡銷售人員以了解額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 十字交叉細分市場分析 - 市場規模與預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 更多人接受愛滋病毒治療
      • 政府對愛滋病毒的認知與舉措不斷增強
      • 產品核可數量增加
    • 抑制因素
      • 嚴格的核准流程
    • 機會
      • 新興市場的高成長潛力
      • 研發線產品增加

第4章 HIV 注射市場：按分銷管道

  • 概述
  • 醫院藥房
  • 藥局/零售藥房
  • 其他

第5章 HIV 注射市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 拉丁美洲、中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他拉丁美洲、中東/非洲

第6章 競爭狀況

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2023年主要企業定位

第7章 公司簡介

  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie Inc.
  • Brii Biosciences
  • Shionogi & Co., Ltd.
Product Code: A312373

The HIV injection market was valued at $1 billion in 2023 and is estimated to reach $5.5 billion by 2033, exhibiting a CAGR of 17.9% from 2024 to 2033. Human immunodeficiency virus (HIV) is a virus that attacks the immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. HIV is primarily transmitted through unprotected sexual intercourse, sharing of contaminated needles, and from an infected mother to her baby during childbirth or breastfeeding. Advances in antiretroviral therapy (ART) have significantly improved the prognosis for people living with HIV, helping to control the virus, prevent the progression to AIDS, and enhance overall quality of life. Regular testing, early detection, and access to medical care are crucial in managing and preventing the spread of HIV.

HIV Injection Market - IMG1

Public awareness, education, and ongoing research remain essential in the global effort to combat this infectious disease. HIV injections are designed to deliver antiretroviral drugs directly into the bloodstream, ensuring effective and consistent levels of the medication in the body. These injections can come in various forms, including intramuscular injections (administered into the muscle) or subcutaneous injections (administered just beneath the skin). The HIV injection market is driven by rise in the number of people suffering from HIV, development and introduction of novel antiretroviral drugs in injectable formulations, rise in demand for long acting and extended delivery HIV prevention and treatment regimens, rise in investment in R and D activities, and growing government initiatives and healthcare policies for HIV.

For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Thus, rise in the number of HIV cases increases the demand for HIV injections and drives the growth of market. In addition, ongoing R and D efforts in the field of HIV treatment led to continuous advancements which is expected to drive the market growth. The introduction of novel antiretroviral drugs, particularly those in injectable formulations, provides healthcare providers and patients with more options for managing the virus, thereby driving market growth. For instance, GlaxoSmithKline plc company manufactured combination of cabotegravir and rilpivirine, a long-acting injectable antiretroviral drug for the treatment of HIV. This regimen, known as Cabenuva (Vocabria and Rekambys in Europe), involves the intramuscular injection of cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. This long-acting injectable regimen has been approved in several high-income countries and has shown promise in maintaining viral suppression.

Furthermore, the government initiatives and healthcare policies, aimed at expanding access to HIV treatment and improving healthcare infrastructure, play a pivotal role, which is expected to drive the market growth. For instance, Ending the HIV Epidemic (EHE) initiative, coordinated by the U.S. Department of Health and Human Services (HHS) aims to reduce the number of new HIV infections in the U.S. by 75% by 2025 and then by at least 90% by 2030. It focuses on leveraging scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to address racial, ethnic, and geographic disparities.

However, the stringent regulatory process for approval and lack of education about HIV prevention in underdeveloped countries are factors responsible for impeding the growth of the HIV injection market. In contrast, rise in number of pipeline drugs for HIV and high growth potential in emerging countries provides lucrative opportunity to the market growth. For instance, in June 2021, ImmunityBio, Inc., a clinical-stage immunotherapy company, announced its HIV clinical pipeline with an HIV cure study using Anktiva (N-803), which is now enrolling participants in the U.S. The trial is expected to study whether Anktiva can control HIV alone or together with combination broadly neutralizing antibodies (bNABs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored.

The HIV injection market is segmented on the basis of distribution channel and region. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global HIV injection market are GlaxoSmithKline plc, Johnson and Johnson, Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd, Theratechnologies Inc., Viriom, Inc., Shionogi & Co., Ltd., AbbVie Inc., and Brii Biosciences. Key players operating in the market have adopted product approvals, partnership, expansion, agreement, and clinical trial as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Others
  • Hospital Pharmacy
  • Drugs Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Shionogi & Co., Ltd.
    • ImmunityBio, Inc.
    • Theratechnologies Inc.
    • Viriom, Inc.
    • Brii Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in number of people receiving HIV therapy
      • 3.4.1.2. Growing awareness & initiatives taken by government for HIV
      • 3.4.1.3. Rise in number of product approvals
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory processes for the approval
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging markets
      • 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hospital Pharmacy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Drugs Stores and Retail Pharmacies
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HIV INJECTION MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Distribution Channel
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Distribution Channel
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Distribution Channel
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Distribution Channel
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Distribution Channel
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Distribution Channel
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Distribution Channel
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Distribution Channel
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Distribution Channel
      • 5.3.3.5. Spain
      • 5.3.3.5.1. Market size and forecast, by Distribution Channel
      • 5.3.3.6. Rest of Europe
      • 5.3.3.6.1. Market size and forecast, by Distribution Channel
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Distribution Channel
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Distribution Channel
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Distribution Channel
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Distribution Channel
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Distribution Channel
      • 5.4.3.5. South Korea
      • 5.4.3.5.1. Market size and forecast, by Distribution Channel
      • 5.4.3.6. Rest of Asia-Pacific
      • 5.4.3.6.1. Market size and forecast, by Distribution Channel
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Distribution Channel
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Brazil
      • 5.5.3.1.1. Market size and forecast, by Distribution Channel
      • 5.5.3.2. Saudi Arabia
      • 5.5.3.2.1. Market size and forecast, by Distribution Channel
      • 5.5.3.3. South Africa
      • 5.5.3.3.1. Market size and forecast, by Distribution Channel
      • 5.5.3.4. Rest of LAMEA
      • 5.5.3.4.1. Market size and forecast, by Distribution Channel

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

  • 7.1. GlaxoSmithKline plc
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
    • 7.1.7. Key strategic moves and developments
  • 7.2. Johnson & Johnson
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Gilead Sciences, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
    • 7.3.7. Key strategic moves and developments
  • 7.4. ImmunityBio, Inc.
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Business performance
    • 7.4.7. Key strategic moves and developments
  • 7.5. F. Hoffmann-La Roche Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
  • 7.6. Theratechnologies Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
    • 7.6.7. Key strategic moves and developments
  • 7.7. Viriom, Inc.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. AbbVie Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Brii Biosciences
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
    • 7.9.6. Business performance
  • 7.10. Shionogi & Co., Ltd.
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Business performance
    • 7.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 02. HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. HIV INJECTION MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. HIV INJECTION MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 06. NORTH AMERICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 07. NORTH AMERICA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 08. U.S. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 09. CANADA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 10. MEXICO HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 11. EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 12. EUROPE HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 13. GERMANY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 14. FRANCE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 15. UK HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 16. ITALY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 17. SPAIN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 18. REST OF EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 21. JAPAN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 22. CHINA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 23. INDIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 24. AUSTRALIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 25. SOUTH KOREA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 26. REST OF ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 27. LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 28. LAMEA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 29. BRAZIL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 30. SAUDI ARABIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 31. SOUTH AFRICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 32. REST OF LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 33. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 34. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 35. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 36. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 37. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 38. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 39. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 40. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 41. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 42. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 43. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 44. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 45. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 46. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 47. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 48. IMMUNITYBIO, INC.: KEY EXECUTIVES
  • TABLE 49. IMMUNITYBIO, INC.: COMPANY SNAPSHOT
  • TABLE 50. IMMUNITYBIO, INC.: PRODUCT SEGMENTS
  • TABLE 51. IMMUNITYBIO, INC.: PRODUCT PORTFOLIO
  • TABLE 52. IMMUNITYBIO, INC.: KEY STRATERGIES
  • TABLE 53. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 54. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 55. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 56. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 57. THERATECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 58. THERATECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 59. THERATECHNOLOGIES INC.: PRODUCT SEGMENTS
  • TABLE 60. THERATECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 61. THERATECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 62. VIRIOM, INC.: KEY EXECUTIVES
  • TABLE 63. VIRIOM, INC.: COMPANY SNAPSHOT
  • TABLE 64. VIRIOM, INC.: PRODUCT SEGMENTS
  • TABLE 65. VIRIOM, INC.: PRODUCT PORTFOLIO
  • TABLE 66. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 67. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 68. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 69. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 70. BRII BIOSCIENCES: KEY EXECUTIVES
  • TABLE 71. BRII BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 72. BRII BIOSCIENCES: PRODUCT SEGMENTS
  • TABLE 73. BRII BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 74. SHIONOGI & CO., LTD.: KEY EXECUTIVES
  • TABLE 75. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
  • TABLE 76. SHIONOGI & CO., LTD.: PRODUCT SEGMENTS
  • TABLE 77. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 78. SHIONOGI & CO., LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HIV INJECTION MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF HIV INJECTION MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN HIV INJECTION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN HIV INJECTION MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL HIV INJECTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. HIV INJECTION MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 16. U.S. HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 17. CANADA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 18. MEXICO HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 19. GERMANY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 20. FRANCE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 21. UK HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 22. ITALY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 23. SPAIN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 24. REST OF EUROPE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 25. JAPAN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 26. CHINA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 27. INDIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 28. AUSTRALIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 29. SOUTH KOREA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. REST OF ASIA-PACIFIC HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. BRAZIL HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. SAUDI ARABIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. SOUTH AFRICA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. REST OF LAMEA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 38. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39. COMPETITIVE DASHBOARD
  • FIGURE 40. COMPETITIVE HEATMAP: HIV INJECTION MARKET
  • FIGURE 41. TOP PLAYER POSITIONING, 2023
  • FIGURE 42. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 45. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. IMMUNITYBIO, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. IMMUNITYBIO, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. THERATECHNOLOGIES INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. THERATECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. BRII BIOSCIENCES: NET REVENUE, 2022-2022 ($MILLION)
  • FIGURE 59. SHIONOGI & CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)